{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:19:30Z","timestamp":1791332370423,"version":"4.3.1"},"reference-count":34,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2026.0040","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:05:56Z","timestamp":1779188756000},"source":"Crossref","is-referenced-by-count":2,"title":["The proposed introduction of a prostate cancer screening program in Germany: Procedure, necessary studies before implementation, benefits, and risks"],"prefix":"10.3238","author":[{"given":"Peter","family":"Albers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agne","family":"Krilaviciute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Seibold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"10.3238\/arztebl.m2026.0040_ref1","doi-asserted-by":"crossref","unstructured":"Roobol MJ, de Vos II, M\u00e5nsson M, et al.: European study of prostate cancer screening\u201423-year follow-up. N Engl J Med 2025; 393: 1669\u201380","DOI":"10.1056\/NEJMoa2503223"},{"key":"10.3238\/arztebl.m2026.0040_ref2","doi-asserted-by":"crossref","unstructured":"Chandran A, van Harten M, Singh D, et al.: Risk-stratified approach to implementing population-based prostate cancer screening in five pilot sites in the European Union: A protocol for the PRAISE-U project. Eur Urol Open Sci 2024; 70: 8\u201317","DOI":"10.1016\/j.euros.2024.09.003"},{"key":"10.3238\/arztebl.m2026.0040_ref3","unstructured":"S3 Leitlinie AWMF Leitlinienprogramm Onkologie: S3 Leitlinie Prostatakarzinom Version 8.1. www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/2025-08-22_LL_Prostatakarzinom_Langversion_8.1.pdf. (last accessed on 13 March 2026)."},{"key":"10.3238\/arztebl.m2026.0040_ref4","doi-asserted-by":"crossref","unstructured":"Krilaviciute A, Becker N, Lakes J, et al.: Digital rectal examination is not a useful screening test for prostate cancer. Eur Urol Oncol 2023; 6: 566\u201373","DOI":"10.1016\/j.euo.2023.09.008"},{"key":"10.3238\/arztebl.m2026.0040_ref5","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG): Prostate cancer screening with a PSA test: IQWiG reports\u2014commission no S19\u201301 [Internet]. Cologne (Germany): Institute for Quality and Efficiency in Health Care (IQWiG); 2020 Jun 10. Institute for Quality and Efficiency in Health Care: Extracts. www.iqwig.de\/download\/s19-01_psa-screening_extract-of-final-report_v1-0.pdf (last accessed on 13 March 2026)."},{"key":"10.3238\/arztebl.m2026.0040_ref6","doi-asserted-by":"crossref","unstructured":"Heijnsdijk EAM, Csan\u00e1di M, Gini A, et al.: All-cause mortality versus cancer-specific mortality as outcome in cancer screening trials: A review and modeling study. Cancer Med 2019; 8: 6127\u201338","DOI":"10.1002\/cam4.2476"},{"key":"10.3238\/arztebl.m2026.0040_ref7","doi-asserted-by":"crossref","unstructured":"Bell KJL, del Mar C, Wrigth G, et al.: Prevalence of incidental prostate cancer: A systematic review of autopsy studies. Int J Cancer 2015; 137: 1749\u201357","DOI":"10.1002\/ijc.29538"},{"key":"10.3238\/arztebl.m2026.0040_ref8","doi-asserted-by":"crossref","unstructured":"Zhao Y, Gulati R, Yang Z, et al.: Projected outcomes of reduced-biopsy management of Grade Group 1 prostate cancer: Implications for relabeling. J Natl Cancer Inst 2025; 117: 685\u201391","DOI":"10.1093\/jnci\/djae296"},{"key":"10.3238\/arztebl.m2026.0040_ref9","doi-asserted-by":"crossref","unstructured":"Shah RB, Paner GP, Cheng L, et al.: Genitourinary pathology society and international society of urological pathology white paper on defining indolent prostate cancer. Am J Surg Pathol 2025; 49: e27\u2013e32","DOI":"10.1097\/PAS.0000000000002425"},{"key":"10.3238\/arztebl.m2026.0040_ref10","doi-asserted-by":"crossref","unstructured":"Cooperberg MR, Braun AE, Berlin A, Kibel AS, Eggener SE, CANCER-GG1 Writing Group: When is prostate cancer really cancer? J Natl Cancer Inst 2025; 117: 402\u20135","DOI":"10.1093\/jnci\/djae200"},{"key":"10.3238\/arztebl.m2026.0040_ref11","doi-asserted-by":"crossref","unstructured":"de Vos II, Marenghi C, Badenchini F, et al.: Long-term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment. BJU Int 2025; 136: 245\u201353","DOI":"10.1111\/bju.16727"},{"key":"10.3238\/arztebl.m2026.0040_ref12","doi-asserted-by":"crossref","unstructured":"Hamdy FC, Donovan JL, Lane JA, et al.: Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2023; 388: 1547\u201358","DOI":"10.1056\/NEJMoa2214122"},{"key":"10.3238\/arztebl.m2026.0040_ref13","doi-asserted-by":"crossref","unstructured":"Carlsson S, Benfante N, Alvim R, et al.: Risk of metastasis in men with Grade Group 2 prostate cancer managed with active surveillance at a tertiary cancer center. J Urol 2020; 203: 1117\u201321","DOI":"10.1097\/JU.0000000000000742"},{"key":"10.3238\/arztebl.m2026.0040_ref14","doi-asserted-by":"crossref","unstructured":"van Harten MJ, Willemse PM, van den Bergh RCN, Roobol MJ: Overview of performance indicators of prostate cancer screening trials. Eur Urol Open Sci 2025; 80: 21\u201332","DOI":"10.1016\/j.euros.2025.08.004"},{"key":"10.3238\/arztebl.m2026.0040_ref15","unstructured":"Robert Koch-Institut: Krebs in Deutschland Prostata. https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Publikationen\/Krebs_in_Deutschland\/kid_2025\/kid_2025_c61_prostata.pdf?__blob=publicationFile (last accessed on 7 April 2026)."},{"key":"10.3238\/arztebl.m2026.0040_ref16","doi-asserted-by":"crossref","unstructured":"Carlsson SV, Carroll PR, Hamdy FC: Reevaluating the definition of clinically significant prostate cancer as grade groups 2 to 5: An imperative for improved risk stratification. J Urol 2025; 213: 238\u201341","DOI":"10.1097\/JU.0000000000004253"},{"key":"10.3238\/arztebl.m2026.0040_ref17","doi-asserted-by":"crossref","unstructured":"Vickers AJ, Ulmert D, Sjoberg DD, et al.: Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40\u201355 and long term risk of metastasis: Case-control study. BMJ 2013; 346: f2023","DOI":"10.1136\/bmj.f2023"},{"key":"10.3238\/arztebl.m2026.0040_ref18","doi-asserted-by":"crossref","unstructured":"Hugosson J, M\u00e5nsson M, Wallstr\u00f6m J, et al.: Prostate cancer screening with PSA and MRI followed by targeted biopsy only. N Engl J Med 2022; 387: 2126\u201337","DOI":"10.1056\/NEJMoa2209454"},{"key":"10.3238\/arztebl.m2026.0040_ref19","doi-asserted-by":"crossref","unstructured":"Eklund M, J\u00e4derling F, Discacciati A, et al.: MRI-targeted or standard biopsy in prostate cancer screening. N Engl J Med 2021; 385: 908\u201320","DOI":"10.1056\/NEJMoa2100852"},{"key":"10.3238\/arztebl.m2026.0040_ref20","doi-asserted-by":"crossref","unstructured":"Hugosson J, Godtman RA, Wallstrom J, et al.: Results after four years of screening for prostate cancer with PSA and MRI. N Engl J Med 2024; 391: 1083\u201395","DOI":"10.1056\/NEJMoa2406050"},{"key":"10.3238\/arztebl.m2026.0040_ref21","doi-asserted-by":"crossref","unstructured":"Nam R, Patel C, Milot L, et al.: Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): A randomized clinical trial. BMJ Open 2022; 12: e059482","DOI":"10.1136\/bmjopen-2021-059482"},{"key":"10.3238\/arztebl.m2026.0040_ref22","doi-asserted-by":"crossref","unstructured":"McHugh JK, Bancroft EK, Saunders E, et al.: Assessment of a polygenic risk score in screening for prostate cancer. N Engl J Med 2025; 392: 1406\u201317","DOI":"10.1056\/NEJMoa2407934"},{"key":"10.3238\/arztebl.m2026.0040_ref23","doi-asserted-by":"crossref","unstructured":"Auvinen A, Tammela TLJ, Mirtti T, et al.: Prostate cancer screening with PSA, Kallikrein Panel, and MRI: The ProScreen randomized trial. JAMA 2024; 331: 1452\u20139","DOI":"10.1001\/jama.2024.3841"},{"key":"10.3238\/arztebl.m2026.0040_ref24","doi-asserted-by":"crossref","unstructured":"Arsov C, Becker N, Hadaschik BA, et al. Prospective randomized evaluation of risk-adapted prostatespecific antigen screening in young men: The PROBASE Trial. Eur Urol 2013; 64: 873\u20135","DOI":"10.1016\/j.eururo.2013.05.022"},{"key":"10.3238\/arztebl.m2026.0040_ref25","doi-asserted-by":"crossref","unstructured":"Krilaviciute A, Kaaks R, Seibold P, et al.: Risk-adjusted screening for prostate cancer-defining the low-risk group by data from the PROBASE Trial. Eur Urol 2024; 86: 493\u2013500","DOI":"10.1016\/j.eururo.2024.04.030"},{"key":"10.3238\/arztebl.m2026.0040_ref26","unstructured":"Krilaviciute A: EAU Abstract. 2026 (in press)."},{"key":"10.3238\/arztebl.m2026.0040_ref27","doi-asserted-by":"crossref","unstructured":"Bratt O, Godtman RA, Jiborn T, et al.: Population-based organised prostate cancer testing: Results from the first invitation of 50-year-old men. Eur Urol 2024; 85: 207\u201314","DOI":"10.1016\/j.eururo.2023.11.013"},{"key":"10.3238\/arztebl.m2026.0040_ref28","doi-asserted-by":"crossref","unstructured":"Boschheidgen M, Albers P, Schlemmer HP, et al.: Multiparametric magnetic resonance imaging in prostate cancer screening at the age of 45 years: Results from the first screening round of the PROBASE Trial. Eur Urol 2024; 85: 105\u201311","DOI":"10.1016\/j.eururo.2023.11.028"},{"key":"10.3238\/arztebl.m2026.0040_ref29","doi-asserted-by":"crossref","unstructured":"Englman C, Adebusoye B, Maffei D, et al.: Magnetic resonance imaging-led risk-adapted active surveillance for prostate cancer: Updated results from a large cohort study. Eur Urol 2025; 88: 167\u201375","DOI":"10.1016\/j.eururo.2025.03.019"},{"key":"10.3238\/arztebl.m2026.0040_ref30","doi-asserted-by":"crossref","unstructured":"Ullrich T, Boschheidgen M, Schweyen CM, et al.: Evaluation of the current status, significance, and availability of prostate MRI und MRI guided biopsy in Germany. Rofo 2025; 197: 945\u201352","DOI":"10.1055\/a-2416-1343"},{"key":"10.3238\/arztebl.m2026.0040_ref31","doi-asserted-by":"crossref","unstructured":"Carlsson SV, Krilaviciute A, Al-Monajjed R, et al.: Risk-adapted prostate cancer screening achieves mammography-like benefits: Evidence and implications for Europe. Eur Urol 2026; 89: 193\u20135","DOI":"10.1016\/j.eururo.2025.12.002"},{"key":"10.3238\/arztebl.m2026.0040_ref32","doi-asserted-by":"crossref","unstructured":"Martin RM, Turner EL, Young GJ, et al.: Prostate-specific antigen screening and 15-year prostate cancer mortality: A secondary analysis of the CAP randomized clinical trial. JAMA 2024; 331: 1460\u201370","DOI":"10.1001\/jama.2024.4011"},{"key":"10.3238\/arztebl.m2026.0040_ref33","doi-asserted-by":"crossref","unstructured":"Roobol MJ, Schr\u00f6der FH, Kranse R, ERSPC, Rotterdam: A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55\u201375 years using a biopsy indication of 3.0 ng\/ml (results of ERSPC, Rotterdam). Prostate 2006; 66: 604\u201312","DOI":"10.1002\/pros.20352"},{"key":"10.3238\/arztebl.m2026.0040_ref34","doi-asserted-by":"crossref","unstructured":"Hugosson J, Carlsson S, Aus G, et al.: Mortality results from the G\u00f6teborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725\u201332","DOI":"10.1016\/S1470-2045(10)70146-7"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2026.0040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:06:51Z","timestamp":1779188811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2026.0040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":34,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2026.0040","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]}}}